Ocular Gene Therapy: A Comprehensive Review with Special Focus on Inflammatory and Immune Responses

Abstract

In recent years, there has been an increasing focus on researching gene therapy. The eye is a subject of high interest in the advancement of gene therapy, since it is one of the rare body organs where gene therapy has been sanctioned by the Food and Drug Administration. Nevertheless, the immune and inflammatory reactions linked to it can make the treatment ineffective or even detrimental. This is especially crucial for the eye, as it is susceptible to inflammation. The intensity of the immune and inflammatory reactions varies depending on the selection of vector and method of delivery. Additionally, the majority of preclinical and clinical research has demonstrated a relationship between the dosage of the vector and the level of humoral response and ocular inflammation. The method of delivery directly influences the level of immune and inflammatory responses. Subretinal administration leads to decreased fluid pressure in the eye and exhibits a superior reaction compared to the intravitreal method. Hence, certain research has shown that subretinal administration could result in a more significant impact. Response that causes inflammation. However, clinical trials utilizing viral vectors injected into the eye have documented numerous instances of vision impairment from intense inflammation within the eye, while delivering genes through the suprachoroidal route has been found to trigger a milder immune response than intravitreal injection.Hence, the suprachoroidal space does not have the same immune protection as the subretinal space. The following ophthalmic gene therapy are mild, and both clinical and preclinical research suggests that these can be managed using topical, localized, or systemic steroids.

Keywords

gene therapy, clinical research, immune and inflammatory reactions, eye inflammation, vision damage.

Introduction

       
           
       
This review aims to give researchers, clinicians, and biotechnology professionals a comprehensive understanding by concentrating on the inflammatory and immune aspects of ocular gene therapy.   

       
           
       
•     Benefits: - Requires minimal invasion - Suitable for outpatient procedures - Enables multiple administrations - Effective in targeting inner retinal layers and ganglion cells.  

       
           
       
 6 Suprachoroidal Delivery   

       
           
       
7 Topical Application

       
           
       
Administering gene therapy vectors in eye drop form is referred to as topical application.  

•     Benefits: - Non-surgical - Easy for patients - Appropriate for multiple uses.  

•     Restrictions: - Restricted access to the back of the eye - Quick removal from the surface of the eye - Inefficiency in reaching retinal targets. 

•     Possible uses: - Gene therapy for eye conditions affecting the cornea - Opportunity for treating diseases in the front part of the eye (e.g., glaucoma).  

8 Comparison of Delivery Methods   

Several factors determine the selection of the delivery method.  

•     The position of the target cells in the eye affects the selection of the delivery method. Intravitreal injection is appropriate for targets located within the inner retina, while subretinal injection is more favorable for targets in the outer retina and RPE. Characteristics of the vector, such as its size and physical attributes, can impact how it spreads and enters the body through various administration techniques.  

•     Effect duration: Certain delivery methods can accommodate multiple administrations, such as intravitreal, while others are usually restricted to just one treatment, such as subretinal.  

•     Safety considerations: The level of invasiveness of the procedure and potential risks should be considered, especially for inherited conditions in young individuals needing treatment.  

•     Immune responses: Various administration techniques can induce different levels of local and systemic immune responses, potentially affecting the treatment's effectiveness and safety.  

•     Feasibility of use in clinical settings may be limited by the technical intricacy of the delivery method and the requirement for specialized equipment or expertise.  

•     Regulatory factors: The regulatory pathway and requirements for clinical development can be influenced by the delivery method chosen. New advancements in delivery methods, like creating new injection tools and researching less invasive ways (like suprachoroidal delivery), focus on enhancing the balance between effectiveness, safety, and practicality in a clinical setting. Continuous research is actively working on enhancing current techniques and investigating novel methods to enhance the results of ocular gene therapy.  

• Inflammatory and Immune Responses in Ocular Gene Therapy   

Even though the eye is considered relatively immune-privileged, ocular gene therapy can provoke inflammatory and immune reactions that could affect the treatment's safety and effectiveness. Comprehending these reactions is essential for creating plans to reduce their impact and enhance treatment results. This part delves into the different elements of the immune reaction to ocular gene therapy, considering innate and adaptive immunity aspects.  

1 Innate Immune Response   

The initial immune response is the primary defense mechanism against foreign entities, such as gene therapy vectors and their parts. In ocular gene therapy, various components of the innate immune system play significant roles.  

1.1 Role of Pattern Recognition Receptors (PRRs)   

PRRs play a vital role in the innate immune system by identifying common molecular patterns linked to pathogens or cellular stress.  

• Important points: - Toll-like receptors (TLRs), specifically TLR9, have the ability to detect viral DNA and induce inflammatory reactions - RIG-I-like receptors (RLRs) identify viral RNA and can stimulate the production of type I interferon - Activation of PRRs results in the generation of pro-inflammatory cytokines and chemokines.  

1.2 Activation of Complement System   

Gene therapy vectors can trigger the activation of the complement system, a group of proteins that boost the capability of antibodies and phagocytic cells to eliminate pathogens.  

• Main points: - Viral vectors can activate both traditional and non-traditional ways of complement systems - The activation of complement can cause inflammation, coating of vector particles, and possible harm to tissues - Certain viral vectors, such as AAV, have developed ways to avoid being neutralized by complement system.  

1.3 Involvement of Innate Immune Cells   

Different types of natural immune cells are involved in the first reaction to gene therapy in the eyes.  

 •    Macrophages in the retina, including both resident microglia and macrophages that migrate into the tissue, have the ability to engulf vector particles and release inflammatory substances.  

Dendritic cells function as cells that present antigens, linking innate and adaptive immune responses.  

•     Natural killer cells may identify and remove cells that display unfamiliar antigens.  

2 Adaptive Immune Response  

The immune response that is adaptive, involving both humoral and cell-mediated immunity, may take longer to develop but can significantly impact the effectiveness and safety of gene therapy in the long run.  

2.1 Humoral Immunity and Antibody Production   

Humoral immunity entails B cells producing antibodies that can deactivate viral vectors and transgene products.  

• Main ideas: - Existing neutralizing antibodies against viral vectors (especially AAV) can lower transduction effectiveness - new antibody responses could form after gene therapy, impacting the success of future treatments - Antibodies targeting the transgene could negate its therapeutic benefits.  

2.2 Cell-Mediated Immunity   

T cells have a key part in cellular immunity by detecting and getting rid of cells showing non-self-antigens.  

• Main points: - CD8+ cytotoxic T lymphocytes have the ability to eliminate transduced cells that display viral or transgene antigens - CD4+ T helper cells aid in the generation of B cell antibodies and CD8+ T cell reactions - Regulatory T cells (Tregs) play a role in regulating the immune response and fostering tolerance.  

2.3 Memory Responses and Implications for Repeated Treatments   

The formation of immune memory could have important consequences for gene therapy in the eye, especially when thinking about the possible requirement for multiple therapies.  

• Main points: - Memory B and T cells can react quickly and strongly when exposed to viral vectors or transgene products again - This response could lower the effectiveness of future treatments and raise the chance of negative immune reactions - Research is

ongoing to find ways to combat memory responses, like changing vector types or using immunomodulation techniques.  

3 Factors Influencing Immune Responses   

Various factors can influence the magnitude and nature of immune responses to ocular gene therapy.  

3.1 Vector-related Factors   

•     Capsid proteins: The protective protein coating of viral carriers can trigger immune reactions, with certain types provoking stronger immunity compared to others.  

•     Transgenic products: The therapeutic protein that is produced may be identified as foreign, particularly when the patient does not have the natural form of the protein. 

•     Higher levels of dosage in general are associated with more potent immune reactions.  

•     Vector cleanliness: Impurities from manufacturing can boost the immune response.   3.2 Host-related Factors   

•     Pre-existing immunity can develop from exposure to wild-type viruses or past gene therapy, leading to the production of neutralizing antibodies and memory T cells.  

•     Genetic background: The immune response strength and type can be influenced by host genetic factors.  

•     Younger people may exhibit stronger immune reactions.  

•     Eye health: The condition of the blood-retinal barrier and the presence of inflammation have an impact on immune privilege.  

3.3 Administration-related Factors   

•     Method of delivery: Various administration techniques (such as intravitreal versus subretinal) can impact the nature and intensity of immune reactions.  

•     Surgical trauma: Invasive delivery methods can lead to local inflammation, potentially boosting immune reactions.  

•     Frequency of dosing: Giving multiple treatments could raise the chance of developing adaptive immune reactions.  

• Strategies to Mitigate Inflammatory and Immune Responses   

Dealing with the difficulties caused by inflammatory and immune reactions is essential for enhancing the safety and effectiveness of ocular gene therapy. This part looks into different tactics being created and used to reduce these reactions.  

1 Vector Engineering and Optimization   

Altering vector designs can decrease immunogenicity and improve transgene expression.  

•     Capsid manipulation: Modifying viral capsids to avoid neutralizing antibodies or improve targeting of particular cell types. 

•     Selection of promoters: Employing cell-specific promoters in order to restrict transgene expression to specific tissues.  

•     Codon optimization: Improving transgene expression and possibly decreasing potential for immune response.  

•     Decreasing CpG content: Lowering the amount of immunostimulatory CpG motifs in the vector genome. 

2 Immunomodulation Strategies   

Ways in pharmacology to reduce or change the immune system's reaction.  

•     Corticosteroids are frequently employed to reduce inflammation present in specific areas or throughout the body.  

•     Cyclosporine and tacrolimus are calcineurin inhibitors that inhibit the activation of T cells.  

•     Sirolimus (rapamycin): mTOR inhibitor that possesses immunosuppressive characteristics.  

•     Inhibitors of complement: Aiming at the complement cascade to decrease inflammation. 

3 Local vs. Systemic Immunosuppression   

Assessing different strategies for regulating the immune system:  

•     Local immune system suppression: Directly delivering immunomodulatory substances to the eye to reduce side effects in the body.  

•     Systemic immune suppression: Increased overall immune suppression, potentially more effective but with higher chance of side effects.  

•     Utilizing local and systemic treatments in combination to enhance effects synergistically. 

4 Tolerance Induction Approaches   

Approaches focused on promoting enduring tolerance to the vector and transgene.  

•     Promotion of Treg expansion to suppress undesired immune responses: Enhancing the generation of regulatory T cells.  

•  Antigen-specific tolerance: Administering vector elements or transgene products in a context that promotes tolerance. 

•     Gene therapy in newborns: Taking advantage of the developing immune system's ability to induce tolerance.  

• Clinical Trials and Current Status   

This part gives a summary of the present state of ocular gene therapy clinical trials and authorized treatments.

1 Successful Treatments and Approved Therapies   

Vortigern (Luxturna) approved for inherited retinal dystrophy caused by RPE65 mutations. Summary of how it was developed, approved, and handled after being marketed.  

2 Ongoing Clinical Trials   

•     Overview of current experiments for different eye-related issues (e.g., choroideremia, Xlinked retinoschisis, achromatopsia).  

•     Conversation about various methods being experimented with (e.g., gene substitution, genetic manipulation, optogenetics). 

3 Challenges and Setbacks Related to Immune Responses   

Examples of trials where immune reactions have presented major obstacles.  

Insights gained from these experiences and how they have influenced following trial layouts. 

4 Lessons Learned from Clinical Experiences  

Significance of choosing the right patients and screening for existing immunity.  

•     Improving the use of vector doses and delivery techniques.  

•     Optimization of immunosuppression regimens.  

•     Considerations for long-term follow-up. 

• Future Perspectives  

This portion examines new developments and upcoming paths in ocular gene therapy, concentrating on tackling immune and inflammatory obstacles.   

1 Novel Vector Designs and Delivery Methods   

•     Creating modified AAV capsids with decreased immune response.      

•     Investigation of non-viral vectors with enhanced safety characteristics.    

•     Improvements in surgical methods and tools have allowed for more accurate and less intrusive procedures.      

2 Advances in Immunomodulation Strategies   

•     Tailored strategies to regulate particular immune pathways.    

•     Creation of new biologics for immune system suppression.  

•     Investigation of using nanoparticles to deliver agents that modulate the immune system.    

3 Gene Editing and In Vivo Gene Therapy   

•     Applications of gene editing technologies like CRISPR-Cas9 in the field of ophthalmology.    

•     Challenges and potential advantages in immune reactions within gene editing strategies.  

4 Combining Gene Therapy with Other Treatment Modalities   

Possible advantages when combining cell therapy methods.      

•     Incorporation with developing drug administration techniques.   

•     Use of neuroprotective or anti-inflammatory therapies in combination.  

CONCLUSION   

Possible benefits from combining cell therapy techniques In recent years, there have been significant advancements in ocular gene therapy, providing optimism for patients with eye disorders that were previously incurable. Yet, the presence of inflammatory and immune reactions pose significant obstacles that could affect the safety and effectiveness of these therapies. This in-depth analysis has examined the complex characteristics of these reactions, from natural defense to learned responses, and the diverse factors affecting their progression. Significant advancements have been made in the field to overcome these obstacles, such as improved vector designs, precise delivery techniques, and new immunomodulation strategies. The potential of ocular gene therapy is highlighted by the success of Luxturna and the positive outcomes of many current clinical trials.      In the future, further progress in vector engineering, delivery technologies, and our knowledge of ocular immunology will be essential in addressing the remaining challenges.  The combination of gene therapy with other advanced techniques like gene editing and cell therapy shows potential for improved and customized treatments. Collaboration among researchers, clinicians, and regulatory bodies will be crucial to safely and effectively translate innovative therapies from the lab to patient care as the field evolves. Continued attempts to tackle inflammatory and immune responses are leading to advancements in ocular gene therapy, which has the potential to transform the treatment of various eye disorders and provide hope for patients globally.

REFERENCES

1. 1. 1. 1. P. Colella et al.Ocular gene therapy: current progress and future prospects Trends Mol. Med.(2009)
         2. C. Bloquel et al.Non-viral ocular gene therapy: potential ocular therapeutic avenues Adv. Drug Deliver. Rev.  (2006)
         3. A. Urtti Challenges and obstacles of ocular pharmacokinetics and drug delivery Adv. Drug Deliver. Rev.  (2006)
         4. E.M. Del Amo et al. Current and future ophthalmic drug delivery systems. A shift to the posterior segment  Drug Discov. Today (2008)
         5. B. Qin et al. Delivery of nucleic acids for ocular gene modulation I.P. Kaur et al.   Nanotherapy for posterior eye diseases J. Control. Release (2014)
         6. A.C. Amrite et al. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration J. Pharm. Pharmacol.  (2005)
         7. J.A. Guy et al. Enhanced short-term plasmid transfection of filtration surgery tissues Invest. Ophthalmol. Vis. Sci.  (2000)
         8. K.S. Balaggan et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors J. Gene Med.  (2006)
         9. R. Gerometta et al. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoidinducible MMP1 gene therapy virus Invest. Ophthalmol. Vis. Sci.  (2010)
         10. I.D. Ladas et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections Retina  (2009)
         11. S. Young et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis  Clin. Exp. Ophthalmol.  (2001)
         12. J. Shen et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor  Gene Ther.  (2006)
         13. S.D. Nadine et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes Mol. Vis.(2008)
         14. J. Bennett et al. AAV2 gene therapy readministration in three adults with congenital blindness Sci. Trans. Med.  (2012) 
         15. T.W. Olsen et al. Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model Invest. Ophthalmol. Vis. Sci.  (2011)  
         16. M.C. Peden et al.  Ab-externo AAV-mediated gene delivery to the suprachoroidal space using a 250-micron flexible microcatheter PLoS One (2011) 
         17. K. Jooss et al. Immunity to adenovirus and adenoassociated viral vectors: implications for gene therapy Gene Ther. (2003)
         18. N. Bessis et al. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms Gene Ther.  (2004) 
         19. M.M. Liu et al. Gene therapy for ocular diseases Br. J. Ophthalmol.  (2011)
         20. L. Jager et al. Emerging adenoviral vectors for stable correction of genetic disorders Curr. Gene Ther.  (2007)
         21. S.H. Min et al.Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis Mol. Ther. (2005)
         22. A. Janssen et al. Effect of late-stage therapy on disease progression in AAV-mediated rescue of photoreceptor cells in the retinoschisin deficient mouse Mol. Ther.  (2008)
         23. A. Sharma et al. Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblasts Brain Res. Bull.  (2010)
         24. A. Sharma et al. AAV serotype influences gene transfer in corneal stroma in vivo Exp. Eye Res.  (2010)
         25. R.W. Herzog Gene therapy for SCID-X1: round 2 Mol. Ther.  (2010)
         26. R. Naik et al. Gene delivery to the retina: focus on non-viral approaches Drug Discov. Today  (2009)
         27. X. Cai et al. Nanoparticle applications in ocular gene therapy Vis. Res.  (2008)
         28. A. Elouahabi et al. Formation and intracellular trafficking of lipoplexes and polyplexes Mol. Ther.(2005)
         29. M. Mével et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA  J. Control. Release  (2010)